Trials / Completed
CompletedNCT03173417
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 177 (actual)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.
Detailed description
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia and determine the best dosage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IM19 CAR-T | T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor |
| DRUG | fludarabine and cyclophosphamide | Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days |
Timeline
- Start date
- 2017-05-23
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2017-06-01
- Last updated
- 2019-05-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03173417. Inclusion in this directory is not an endorsement.